KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Average (2016 - 2025)

Historic Equity Average for Inovio Pharmaceuticals (INO) over the last 15 years, with Q3 2025 value amounting to $10.4 million.

  • Inovio Pharmaceuticals' Equity Average fell 8777.84% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 8777.84%. This contributed to the annual value of $92.9 million for FY2024, which is 4529.1% down from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Equity Average stood at $10.4 million, which was down 8777.84% from $39.9 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' Equity Average's 5-year high stood at $545.1 million during Q2 2021, with a 5-year trough of $10.4 million in Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $184.3 million (2023), whereas its average is $228.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 43955.94% in 2021, then tumbled by 8777.84% in 2025.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Equity Average stood at $426.6 million in 2021, then crashed by 42.68% to $244.5 million in 2022, then tumbled by 47.76% to $127.8 million in 2023, then crashed by 44.41% to $71.0 million in 2024, then plummeted by 85.35% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $39.9 million for Q2 2025, and $59.9 million during Q1 2025.